24/04/2014 21:04:17 Free Membership Login

Allergy Therapeutics Company Financial Information

 Company name: Allergy Thera.
 EPIC: AGY Trading Currency: GBX
 Market Sector: AIM ISIN: GB00B02LCQ05
 Market Segment: AIM Share Type: DE
 WWW Address:  Description: ORD 0.1P
 Industry Sector: PHARMACEUTICALS & BIOTECHNOLOGY
 Price Price Change [%] Bid Ask Open High Low Volume
 19.00 mages.advfn.com/imagesnew/2/us/dot 0.0 [0.00] 18.75 19.25 19.00 19.00 19.00 30,151
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 77.87 409.87 0.41 0.13 - 146.15 - 32.75 - 6.75

Allergy Therapeutics Key Figures

(at previous day's close)
Market Cap.77.87m
Shares In Issue409.87m
Prev. Close19.00
PE Ratio146.15 
Dividend Yield-%
EPS - basic0.13p
Dividend PS-p
Dividend Cover- 
Cash Flow PS0.59p
Return On Equity (ROE)3.65%
Operating Margin1.10%
PEG Factor-3.04 
EPS Growth Rate-48.00%
Dividends PS Growth Rate-%
Net Debt13.04m
Gross Gearing49.35%
Quick Assets8.64m
Net Working Capital7.04m
Intangibles / Fixed Assets27.33%
Turnover PS9.58p
Pre-Tax Profit PS0.11p
Retained Profit PS0.13p
Cash PS0.31p
Net Cash PS-1.55p
Net Tangible Asset Value PS *2.63p
Net Asset Value PS3.58p
Spread0.50 (2.60%) 

Allergy Therapeutics Balance Sheet

LSE:AGY:Liabilities+EQLSE:AGY:Assets

Allergy Therapeutics Share Price

Sample Period HighLow
1 week19.5018.75
4 weeks23.0018.75
12 weeks32.759.13
1 year32.756.75

Allergy Therapeutics Share Price (5 years)

Allergy Therapeutics Historic Returns

Giorni da oggi OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week19.50-0.50-2.5619.170.3119.12
4 weeks23.00-4.00-17.3920.070.5420.18
12 weeks9.139.88108.2218.520.8020.18
26 weeks7.7511.25145.1612.770.5017.08
1 year10.508.5080.9511.170.7212.40
3 years16.382.6316.0311.180.4411.45
5 years12.756.2549.0211.750.3511.79

Allergy Therapeutics Key Management Ratios

Allergy Therapeutics Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio24.01 
PE Ratio146.15 
Tobin's Q Ratio 2.75 
Tobin's Q Ratio (excl. intangibles)3.23 
Dividend Yield-%
Market-to-Book Ratio5.31 
Price-to-Pre-Tax Profit PS180.27 
Price-to-Retained Profit PS145.29 
Price-to-Cash Flow PS32.02 
Price-to-Sales PS1.98 
Price-to-Net Tangible Asset Value PS7.24 
Price-to-Cash PS61.95 
Net Working Capital PS1.72 
Price Pct to Working Capital PS11.07%
Earnings Yield0.68%
Average PE54.82 
Years in average3 
PE to PE average266.60%

Allergy Therapeutics Financial Ratios

(Leverage Ratios)
Debt Ratio31.26%
Debt-to-Equity Ratio0.45 
Debt-to-Equity Ratio (excl. Intgbl)0.62 
Debt-to-Equity Market Value0.09 
Net Gearing45.01%
Net Gearing (excl. Intangibles)52.03%
Gross Gearing49.35%
Gross Gearing (excl. Intangibles)57.05%
Gearing Under 1 Year26.31%
Gearing Under 1 Year (excl. Intgbl)30.41%
Assets/Equity1.97 
Cash/Equity8.57 
(Liquidity Ratios)
Net Working Capital to Total Assets24.29%
Current Ratio1.92 
Quick Ratio (Acid Test)1.13 
Liquidity Ratio0.16 
Cash & Equiv/Current Assets8.58%
(Solvency Ratios)
Enterprise Value83.29m
CFO/Sales0.06 
CFO/Attributable Profit4.54 
CFO/Assets0.08 
CFO/Debt0.17 
Total Debt/Equity Market Value0.18 
Total Debt/Sales0.36 
Total Debt/Pre-Tax Profit33.09 
Total Debt14.29m
Total Debt/Net Current Assets2.03%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs4 
Beta (60-Mnth)Beta (36-Mnth)
0.41420.7743
Alpha (60-Mnth)Alpha (36-Mnth)
0.02050.0170

Allergy Therapeutics Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)2.02%
Return On Assets (ROA)1.89%
Net Profit Margin1.36%
Assets Turnover1.39 
Return On Equity (ROE)3.65%
Return On Investment (ROI)2.59%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio3.66%
Net Income Of Revenues1.36%
(Asset Utilisation Multiples)
Shareholders Equity Turnover2.68 
Fixed Assets Turnover2.71 
Current Assets Turnover2.84 
Net Working Capital Turnover 
Inventory Turnover6.20 
(Other Operating Ratios)
Total Assets-to-Sales0.72 
Debtors-to-Sales15.76%
Debt Collection Period57.53Days

Allergy Therapeutics Dividends

Sorry No Data Available

Allergy Therapeutics Fundamentals

 30 Jun 2010 (GBP)30 Jun 2011 (GBP)30 Jun 2012 (GBP)30 Jun 2013 (GBP)
turnover40.75100.00%41.55100.00%41.28100.00%39.28100.00%m
pre tax profit-0.12-0.28%-2.31-5.57%0.641.55%0.431.10%m
attributable profit0.591.44%-2.66-6.41%0.821.99%0.541.36%m
retained profit0.591.44%-2.66-6.41%0.821.99%0.541.36%m
eps - basic0.20 -0.86 0.25 0.13 
eps - diluted0.19 -0.86 0.24 0.13 
dividends per share- - - - 

Allergy Therapeutics Balance Sheet

 30 Jun 2010 (GBP)30 Jun 2011 (GBP)30 Jun 2012 (GBP)30 Jun 2013 (GBP)
LSE:AGY:Liabilities+EQLSE:AGY:AssetsLSE:AGY:Liabilities+EQLSE:AGY:AssetsLSE:AGY:Liabilities+EQLSE:AGY:AssetsLSE:AGY:Liabilities+EQLSE:AGY:Assets
 30 Jun 2010 (GBP)30 Jun 2011 (GBP)30 Jun 2012 (GBP)30 Jun 2013 (GBP)
ASSETS
fixed assets fixed assets8.9430.70%8.8128.77%7.5627.22%7.3425.33%m
intangibles intangibles3.3611.53%4.4114.39%4.6016.56%3.9113.50%m
fixed investments fixed investments2.026.93%2.498.14%2.579.26%3.0610.57%m
current assets - other current assets - other--%--%0.481.74%--%m
stocks stocks6.8923.68%6.7822.14%6.6523.96%6.0120.76%m
debtors debtors3.3911.64%7.0923.14%5.0018.00%7.3925.50%m
cash & securities cash & securities4.5215.52%1.053.42%0.903.25%1.264.34%m
TOTAL29.12100%30.62100%27.75100%28.96100%m
LIABILITIES
creditors - short creditors - short9.9834.29%11.1536.40%7.7527.91%7.6226.31%m
creditors - long creditors - long15.2552.36%17.3456.61%5.4219.51%6.6723.04%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
TOTAL25.2386.65%28.4893.01%13.1647.42%14.2949.35%m
EQUITY
ord cap, reserves ord cap, reserves3.8913.35%2.146.99%14.5952.58%14.6750.65%m
prefs, minorities prefs, minorities--%--%--%--%m
TOTAL3.8913.35%2.146.99%14.5952.58%14.6750.65%m
OTHER
NAV Basic- - - - 
NAV Diluted- - - - 

Allergy Therapeutics Cash Flow Statement

30 Jun 2010 (GBP)30 Jun 2011 (GBP)30 Jun 2012 (GBP)30 Jun 2013 (GBP)
Operating CF1.70-2.032.882.43m
Pre-Financing CF-0.31-4.311.311.28m
Retained CF4.59-3.55-1.421.42m

Allergy Therapeutics Brokers

NameActivityTypeMnemonicCode
Nomura Code Securities LimitedMarket Maker(MMF)Broker/DealerCODECODCGB21
Evolution Securities LimitedMarket Maker(MMF)Broker/DealerEVOEVBGGB21MMT
Canaccord Genuity LimitedMarket Maker(MMF)Broker/DealerCANAHOARGB21001
Jefferies International LtdMarket Maker(MMF)Broker/DealerJEFFJEFFGB2X
Liberum Capital LimitedMarket Maker(MMF)Broker/DealerLIBCLCAPGB21
Piper Jaffray LtdMarket Maker(MMF)Broker/DealerPIPRPIPRGB21
Shore Capital Stockbrokers LtdMarket Maker(MMF)Broker/DealerSCAPSHOCGB21
Winterflood Securities LtdMarket Maker(MMF)Broker/DealerWINSWNTSGB2LBIC



NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us lse agy140424 21:04